Corresponding Author: Gregory S. Calip, PharmD, MPH, PhD, Flatiron Health, Inc, 233 Spring St, New York, NY 10013 (gregory.calip@flatiron.com).
Published Online: June 17, 2021. doi:10.1001/jamaoncol.2021.1715
Conflict of Interest Disclosures: Dr Calip reported receiving grants from Pfizer outside the submitted work. Drs Calip, Miksad, and Sarkar report current employment with Flatiron Health, Inc, which is an independent subsidiary of the Roche group, and stock ownership in Roche. Drs Miksad and Sarkar also reported equity ownership in Flatiron Health, Inc (initiated before acquisition by Roche in 2018).
1.Thompson
MA , Henderson
JP , Shah
PK ,
et al; for the COVID-19 and Cancer Consortium. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19.
JAMA Oncol. Published online June 17, 2021. doi:
10.1001/jamaoncol.2021.1799Google Scholar 5.Kaiser
P , Arnold
AM , Benkeser
D ,
et al. Comparing methods to address bias in observational data: statin use and cardiovascular events in a US cohort.
Int J Epidemiol. 2018;47(1):246-254. doi:
10.1093/ije/dyx179
PubMedGoogle ScholarCrossref 6.Arbogast
PG , Ray
WA . Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders.
Am J Epidemiol. 2011;174(5):613-620. doi:
10.1093/aje/kwr143
PubMedGoogle ScholarCrossref 7.Safety, tolerability, and efficacy of anti-spike (S) SARS-CoV-2 monoclonal antibodies for hospitalized adult patients with COVID-19. ClinicalTrials.gov identifier: NCT04426695. Accessed April 23, 2021.
https://clinicaltrials.gov/ct2/show/NCT04426695 8.Chubak
J , Boudreau
DM , Wirtz
HS , McKnight
B , Weiss
NS . Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival.
J Natl Cancer Inst. 2013;105(19):1456-1462. doi:
10.1093/jnci/djt211
PubMedGoogle ScholarCrossref